EGFR and gastric cancer: Given that PI3K pathway alterations have been linked to resistance to EGFR-targeted therapies, our findings suggest that NHW GC patients with PI3K alterations may benefit from alternative therapeutic strategies targeting this pathway, such as PI3K inhibitors or combination therapies.